The United States of America, As Represented by the Secretary, Department of Health and Human Services

Xiamen University

Xiamen Innovax Biotech Co., Ltd.

Yang Sheng Tang Company Limited

Man Chen

Barney S Graham

Baoshan Zhang

Michael Gordon Joyce

Peter D Kwong

Yongping Yang

Ivelin Georgiev

Jason Scott McLellan

Guillaume Stewart-Jones

Marie Pancera

Mallika Sastry

Cinque Soto

Tongqing Zhou

Masaru Kanekiyo

Jeffrey C Boyington

Gwo-Yu Chuang

Wing-Pui Kong

Aliaksandr Druz

Yaroslav Tsybovsky

Li Ou

Gilad Ofek

Jason Gorman

Ulrich Baxa

Paul Thomas

Joseph Van Galen

Lei Chen

Sanjay Srivatsan

Emily Rundlet

John R Mascola

Ningshao Xia

John Mascola

Liangmin Huang

Zizheng Zheng

Min Zhao

Jason S Mclellan

Ivelin Stefanov Georgiev

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Substitutions-modified prefusion RSV F proteins and their use

Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.

The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.

Epitope of RSV fusion protein and antibody recognizing the same

Growing community of inventors

Bethesda, MD, United States of America

Man Chen